title: HVTN100 phase 1/2 vaccine trial results promising; phase 2b/3 trial to commence.
authors.affiliation: Harper Health & Science Communications LLC, Seattle, Washington, USA.
authors.forename: Kristin N
authors.initials: KN
authors.lastname: Harper
mesh_terms: D016915:AIDS Vaccines / Q000008:administration & dosage* / Q000276:immunology*; D000163:Acquired Immunodeficiency Syndrome / Q000517:prevention & control*; D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000293:Adolescent; D000328:Adult; D000914:Antibodies, Viral / Q000097:blood; D005260:Female; D006801:Humans; D007115:Immunization Schedule; D008297:Male; D016032:Randomized Controlled Trials as Topic; D013019:South Africa; D013601:T-Lymphocytes / Q000276:immunology; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D016915:AIDS Vaccines; D000276:Adjuvants, Immunologic; D000914:Antibodies, Viral